Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: A double-blind, phase III comparison study versus erythromycin 2% cream

European Journal of Dermatology

Volumn 16, Issue 1, 2006, Pages 48-55

  Plewig, Gerd ^a   Holland, Keith T ^b   Nenoff, Pietro ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Laboratorium fur Medizinische Mikrobiologie   (Germany)

Author keywords

Acne; Antibiotic resistance; Coagulase negative staphylococci; Erythromycin; Nadifloxacin; Propionibacterium acnes

Indexed keywords

ERYTHROMYCIN; NADIFLOXACIN;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BURN; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMEDO; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERYTHEMA; FEELING TENSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROPIONIBACTERIUM ACNES; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ABRASION; SKIN BURNING SENSATION; WARM SKIN;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICROBIAL SENSITIVITY TESTS; PROBABILITY; QUINOLIZINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 32344453071     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol 2003; 19: 1-10.
2. Leyden JJ. Pathogenesis of acne vulgaris. Int J Dermatol 1976; 15: 490-6.
3. Oberemok SS, Shalita AR. Acne vulgaris, I: pathogenesis and diagnosis. Cutis 2002; 70: 101-5.
4. Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc 2001; 34: 29-40.
5. Gollnick H, Schramm M. Topical therapy in acne. J Eur Acad Dermatol Venereol 1998; 11: S8-S12; [discussion S28-9].
6. Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol 2003; 83: 241-8.
7. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41-5.
8. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51-7.
9. Kawabata S, Ohguro K, Mukai F, Ohmori K, Miyamoto H, Tamaoka H. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
10. Kawabata S, Masada H, Wakebe H, Ohmori K, Tamaoka H. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 2: Therapeutic effect of OPC-7251 cream on experimental infection model in mice. Chemotherapy 1989; 37: 1179-83.
11. OPC-7251 Acne Study Group. Clinical assesstment of 1% nadifloxacin cream against superficial bacterial skin infection. Nishinihon J Dermatol 1996; 58: 296-304.
12. Orfanos CE. Double-blind pilot study of nadifloxacin vs. erythromycin in patients with acne vulgaris. Data on file. 1992; [Study report number 54-90-101].
13. Asada Y. Clinical assessment of 1% OPC-7251 cream, a new topical antibacterial agent in acne vulgaris. Nishinihon J Dermatol 1990; 52: 790-4.
14. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991; 25: 674-81.
15. Mori S, Kano Y, Goto Y, et al. Investigation of optimal dose of OPC-7251 cream, a topical antibacterial agent: Double-blind comparison study in acne vulgaris. Nishinihon J Dermatol 1990; 52: 781-9.
16. Muto N, Mitoh Y, Yamamoto I. Development of a sensitive enzyme immunoassay for OPC-7251, a novel antimicrobial agent for percutaneous application. J Immunoassay 1990; 11: 1-16.
17. Asada Y. Pharmacokinetics and safely evaluation of OPC-7251 cream after topical application in healthy volunteers. Jpn Pharmacol Ther 1990; 18: 353-66.
18. CMPM working parts on efficacy of medical products. Good Clinical Practice for Trials on Medical Products in the European Community. Brussels: EC, 1990.
19. The Association of the British Pharmaceutical Industry. Guidelines on Good Clinical (Research). London: Practice. ABPI, 1988.
20. The Association of the British Pharmaceutical Industry. Clinical Trial Compensation Guidelines. London: ABPI, 1991.
21. Der Bundesminister für Jugend. Frauen, und Gesundheit. Grundsätze für die ordnungsgemäße Durchführung der klinischen Prüfung von Arzneimitteln. Bundesanzeiger, 1987; [16617].
22. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-5.
23. Williamson P, Kligman AM. A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965; 45: 498-503.
24. Miles AA, Misra SS. The estimation of the bacteriocidal power of blood. J Hygiene (Camb) 1938; 38: 732-48.
25. Vogt K, Hermann J, Blume U, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis 1992; 11: 943-5.
26. Bojar RA, Hittel N, Cunliffe WJ, Holland KT. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49: 164-7.
27. Leyden JJ. Antibiotic resistant acne. Cutis 1976; 17: 593-6.
28. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54-6.
29. Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004; 73: 6-10.
30. Hayakawa R, Ogino Y, Arisu K, Ninagawa Y. Safety evaluation of topical OPC-7521 synthetic antibacterial agent. Skin Research 1990; 32: 217-30.
31. Vogt K, Hahn H, Hermann J, et al. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Drugs 1995; 49: 266-8.
32. Nishijima S, Nakagawa M, Tsuboi N, et al. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones. J Int Med Res 1996; 24: 12-6.
33. Nishijima S, Kurokawa I, Kawabata S. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. J Int Med Res 1996; 24: 473-7.
34. Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999; 9: 25-8.
35. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46.
36. Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002; 49: 455-65.
37. Nishijima S, Kurokawa I, Nakaya H. Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J Infect Chemother 2002; 8: 187-9.
38. Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy 2004; 50: 196-201; [Epub 2004 Sep 23].